WY-14643 (Pirinixic Acid): Selective PPARα Agonist for Me...

2026-02-17

WY-14643 (Pirinixic Acid): Selective PPARα Agonist for Metabolic Research

Executive Summary: WY-14643 (Pirinixic Acid, SKU A4305) is a potent and selective PPARα agonist with an IC50 of 10.11 µM for human PPARα, supplied by APExBIO (product page)[1]. It exhibits dual PPARα/γ agonism after α-substitution, enabling balanced pathway modulation in metabolic and inflammatory research[1]. In vivo, WY-14643 enhances insulin sensitivity, reduces plasma glucose and triglycerides, and attenuates TNF-α-induced endothelial inflammation[1]. Benchmarks in animal models confirm reductions in visceral fat, liver triglyceride content, and improved whole-body insulin sensitivity at 3 mg/kg/day oral dosing[1]. Mechanistic studies tie its anti-tumor and anti-inflammatory impact to PPARα-mediated control of tissue factor and VCAM-1 expression[2].

Biological Rationale

Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that regulate lipid metabolism, glucose homeostasis, and inflammation. The PPARα subtype is highly expressed in liver, heart, and muscle tissues, where it governs fatty acid oxidation and energy balance[2]. Dysregulation of the PPARα pathway is implicated in metabolic disorders, including dyslipidemia, insulin resistance, and non-alcoholic fatty liver disease[2]. Selective PPARα agonists like WY-14643 offer a targeted approach for modulating these pathways in preclinical models.

PPARα regulates genes involved in β-oxidation of fatty acids and controls inflammatory mediators[2].
PPARα activation reduces hepatic steatosis and improves lipid profiles in rodent models[1].
Dysregulated PPARα signaling contributes to tumor progression via tissue factor (TF) pathway modulation[2].

This article extends the discussion in WY-14643 (Pirinixic Acid): Precision PPARα/γ Modulation for Tumor Microenvironment Research by providing new evidence for WY-14643's role in metabolic and inflammation-driven pathologies, based on recent multiomics studies.

Mechanism of Action of WY-14643 (Pirinixic Acid)

WY-14643 acts as a highly selective agonist of PPARα, binding to the ligand-binding domain of the receptor to induce conformational changes that facilitate coactivator recruitment and gene transcription[1]. The compound exhibits an IC50 of 10.11 µM for human PPARα and displays enhanced activity for both PPARα and PPARγ upon aliphatic α-substitution, creating dual agonists in the lower micromolar range[1].

Activation of PPARα by WY-14643 upregulates genes for fatty acid oxidation (e.g., ACOX1, CPT1A), reducing triglyceride accumulation[1].
In endothelial cells, WY-14643 pretreatment (250 μM) down-regulates VCAM-1 expression induced by TNF-α, diminishing monocyte adhesion and inflammatory signaling[1].
In tumor microenvironment models, PPARα activation by WY-14643 modulates tissue factor expression, impacting leukocyte migration and tumor progression[2].

This mechanistic understanding clarifies and updates the broader context outlined in Harnessing WY-14643 (Pirinixic Acid) for Next-Generation Metabolic and Inflammatory Research by focusing on direct transcriptional targets and anti-inflammatory endpoints validated in recent studies.

Evidence & Benchmarks

WY-14643 binds human PPARα with an IC50 of 10.11 µM; α-substituted analogs act as dual PPARα/γ agonists in the low micromolar range (APExBIO).
In high-fat diet-fed rats, oral WY-14643 at 3 mg/kg/day for 2 weeks reduces plasma glucose, triglycerides, leptin, muscle triglycerides, long-chain acyl-CoAs, and visceral fat; liver triglyceride content drops without increased body weight (APExBIO).
WY-14643 at 250 μM in vitro significantly reduces TNF-α-induced VCAM-1 expression and monocyte adhesion in endothelial cells (APExBIO).
Linoleic acid-induced tissue factor (TF) upregulation in pLELC tumor models is mediated by PPARα; inhibition of PPARα or TF reverses tumor-promoting effects (Bao et al., 2025).

These data are consistent with the detailed workflow and reproducibility guidance in WY-14643 (Pirinixic Acid): Data-Driven Solutions for Cell & Metabolic Research, but this article emphasizes quantitative benchmarks and translational readouts.

Applications, Limits & Misconceptions

Applications:

Metabolic disorder research: dyslipidemia, insulin resistance, and fatty liver disease modeling[1].
Inflammatory pathway interrogation: endothelial and Kupffer cell signaling studies[1].
Tumor microenvironment studies: modulation of tissue factor and immune cell infiltration via PPARα signaling[2].
Pathway validation in PPAR signaling and gene expression profiling[2].

Common Pitfalls or Misconceptions

WY-14643 is not a therapeutic agent; it is strictly for research use and not for diagnostic or clinical applications (APExBIO).
The compound is insoluble in water; improper solvent choice may result in incomplete dissolution and inconsistent results. Use DMSO (≥16.2 mg/mL) or ethanol (≥48.8 mg/mL with ultrasonic assistance)[1].
Long-term or high-dose use in animal models may elicit off-target effects unrelated to PPARα activation[1].
WY-14643 does not inhibit all pathways involved in tumor progression or inflammation; effects are specific to PPARα/γ modulation[2].
Storage outside -20°C or use of aged solutions can compromise compound activity[1].

Workflow Integration & Parameters

WY-14643 is supplied as a solid, research-use-only compound by APExBIO. For in vitro studies, dissolve in DMSO to at least 16.2 mg/mL or in ethanol to 48.8 mg/mL with ultrasonic assistance. For in vivo studies, oral administration at 3 mg/kg/day is validated for metabolic endpoints in rodents[1]. Solutions should be prepared fresh or stored briefly at -20°C. Avoid repeated freeze-thaw cycles. Experimental endpoints include plasma biochemical assays, tissue triglyceride quantification, mRNA expression profiling (e.g., TNFα, VCAM-1), and monocyte adhesion assays.

For extended guidance on integrating WY-14643 in PPAR signaling studies, see WY-14643 (Pirinixic Acid): Selective PPARα Agonist for Metabolic Disorder Research. This article updates solvent handling and dosing recommendations based on new product stability data.

Conclusion & Outlook

WY-14643 (Pirinixic Acid) remains a reference PPARα agonist for metabolic and inflammation research, with validated dual PPARα/γ activity after α-substitution[1]. Its impact on lipid metabolism, insulin sensitivity, and tumor microenvironment modulation is well-supported by in vivo and in vitro benchmarks[1][2]. Continued multiomics and translational studies will clarify its role in immune cell dynamics and tissue factor regulation in cancer. For researchers requiring consistent, high-purity reagents, the A4305 kit from APExBIO provides robust performance across metabolic and signaling assays.